Neglected No More: Emerging Cellular Therapies in Traumatic Injury

Traumatic injuries are a leading cause of death and disability in both military and civilian populations. Given the complexity and diversity of traumatic injuries, novel and individualized treatment strategies are required to optimize outcomes. Cellular therapies have potential benefit for the treatment of acute or chronic injuries, and various cell-based pharmaceuticals are currently being tested in preclinical studies or in clinical trials. Cellular therapeutics may have the ability to complement existing therapies, especially in restoring organ function lost due to tissue disruption, prolonged hypoxia or inflammatory damage. In this article we highlight the current status and discuss future directions of cellular therapies for the treatment of traumatic injury. Both published research and ongoing clinical trials are discussed here.

Automated summary

Traumatic injuries are a major cause of death and disability, requiring novel and personalized treatment strategies for optimal outcomes. Cellular therapies have shown potential in treating acute or chronic injuries, with various cell-based pharmaceuticals currently under preclinical studies or clinical trials. These therapies may complement existing treatments by restoring lost organ function due to tissue disruption, prolonged hypoxia, or inflammatory damage.